Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

NASDAQ:AXSM - Nasdaq - US05464T1043 - Common Stock - Currency: USD

109.39  +4.16 (+3.95%)

After market: 109 -0.39 (-0.36%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AXSM. AXSM was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AXSM have multiple concerns. AXSM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AXSM had negative earnings in the past year.
AXSM had a negative operating cash flow in the past year.
In the past 5 years AXSM always reported negative net income.
In the past 5 years AXSM always reported negative operating cash flow.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of AXSM (-38.59%) is comparable to the rest of the industry.
AXSM's Return On Equity of -337.87% is on the low side compared to the rest of the industry. AXSM is outperformed by 75.65% of its industry peers.
Industry RankSector Rank
ROA -38.59%
ROE -337.87%
ROIC N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

AXSM has a Gross Margin of 91.48%. This is amongst the best in the industry. AXSM outperforms 95.34% of its industry peers.
AXSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AXSM has more shares outstanding
AXSM has a worse debt/assets ratio than last year.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.74 indicates that AXSM is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.74, AXSM is in the better half of the industry, outperforming 70.47% of the companies in the same industry.
AXSM has a Debt/Equity ratio of 2.62. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.62, AXSM is not doing good in the industry: 80.31% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.62
Debt/FCF N/A
Altman-Z 2.74
ROIC/WACCN/A
WACC10.13%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.57 indicates that AXSM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.57, AXSM is not doing good in the industry: 67.88% of the companies in the same industry are doing better.
AXSM has a Quick Ratio of 1.51. This is a normal value and indicates that AXSM is financially healthy and should not expect problems in meeting its short term obligations.
AXSM has a worse Quick ratio (1.51) than 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.51
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.12% over the past year.
AXSM shows a strong growth in Revenue. In the last year, the Revenue has grown by 69.83%.
EPS 1Y (TTM)22.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.92%
Revenue 1Y (TTM)69.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%72.13%

3.2 Future

Based on estimates for the next years, AXSM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.56% on average per year.
The Revenue is expected to grow by 46.11% on average over the next years. This is a very strong growth
EPS Next Y39.19%
EPS Next 2Y50.12%
EPS Next 3Y52.37%
EPS Next 5Y39.56%
Revenue Next Year58.86%
Revenue Next 2Y58.94%
Revenue Next 3Y57.33%
Revenue Next 5Y46.11%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXSM. In the last year negative earnings were reported.
AXSM is valuated quite expensively with a Price/Forward Earnings ratio of 72.05.
Based on the Price/Forward Earnings ratio, AXSM is valued a bit cheaper than the industry average as 67.36% of the companies are valued more expensively.
AXSM's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 35.78.
Industry RankSector Rank
PE N/A
Fwd PE 72.05
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AXSM does not grow enough to justify the current Price/Earnings ratio.
AXSM's earnings are expected to grow with 52.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.12%
EPS Next 3Y52.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXSM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (8/13/2025, 8:00:00 PM)

After market: 109 -0.39 (-0.36%)

109.39

+4.16 (+3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners75.69%
Inst Owner Change-0.13%
Ins Owners1.39%
Ins Owner Change-0.14%
Market Cap5.39B
Analysts86.4
Price Target180.14 (64.68%)
Short Float %8.97%
Short Ratio5.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)9.8%
Max EPS beat(2)13.71%
EPS beat(4)3
Avg EPS beat(4)-4.58%
Min EPS beat(4)-48.67%
Max EPS beat(4)13.71%
EPS beat(8)3
Avg EPS beat(8)-17.51%
EPS beat(12)5
Avg EPS beat(12)-8.9%
EPS beat(16)8
Avg EPS beat(16)-4.74%
Revenue beat(2)1
Avg Revenue beat(2)2.65%
Min Revenue beat(2)-0.65%
Max Revenue beat(2)5.96%
Revenue beat(4)2
Avg Revenue beat(4)2.02%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)1.72%
Revenue beat(12)8
Avg Revenue beat(12)24.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.47%
PT rev (3m)-0.48%
EPS NQ rev (1m)-1.29%
EPS NQ rev (3m)-8.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.67%
Revenue NQ rev (1m)-1.02%
Revenue NQ rev (3m)-1.32%
Revenue NY rev (1m)-0.59%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 72.05
P/S 10.88
P/FCF N/A
P/OCF N/A
P/B 73.71
P/tB 311.35
EV/EBITDA N/A
EPS(TTM)-5.07
EYN/A
EPS(NY)1.52
Fwd EY1.39%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.45
OCFYN/A
SpS10.05
BVpS1.48
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.59%
ROE -337.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.48%
FCFM N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 2.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.53%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.51
Altman-Z 2.74
F-Score5
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.92%
EPS Next Y39.19%
EPS Next 2Y50.12%
EPS Next 3Y52.37%
EPS Next 5Y39.56%
Revenue 1Y (TTM)69.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%72.13%
Revenue Next Year58.86%
Revenue Next 2Y58.94%
Revenue Next 3Y57.33%
Revenue Next 5Y46.11%
EBIT growth 1Y24.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.99%
EBIT Next 3Y56.53%
EBIT Next 5Y46.22%
FCF growth 1Y-8.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.2%
OCF growth 3YN/A
OCF growth 5YN/A